88 related articles for article (PubMed ID: 10570424)
1. Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing malignant mesothelioma.
Thylén A; Wallin J; Martensson G
Cancer; 1999 Nov; 86(10):2000-5. PubMed ID: 10570424
[TBL] [Abstract][Full Text] [Related]
2. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma.
Hedman M; Arnberg H; Wernlund J; Riska H; Brodin O
Anticancer Res; 2003; 23(1B):531-6. PubMed ID: 12680141
[TBL] [Abstract][Full Text] [Related]
3. High pleural fluid hyaluronan concentrations in rheumatoid arthritis.
Söderblom T; Pettersson T; Nyberg P; Teppo AM; Linko L; Riska H
Eur Respir J; 1999 Mar; 13(3):519-22. PubMed ID: 10232419
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronan in pleural effusions and in serum.
Hillerdal G; Lindqvist U; Engström-Laurent A
Cancer; 1991 May; 67(9):2410-4. PubMed ID: 2013045
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronan production increases the malignant properties of mesothelioma cells.
Li Y; Heldin P
Br J Cancer; 2001 Aug; 85(4):600-7. PubMed ID: 11506502
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
Creaney J; Francis RJ; Dick IM; Musk AW; Robinson BW; Byrne MJ; Nowak AK
Clin Cancer Res; 2011 Mar; 17(5):1181-9. PubMed ID: 21177406
[TBL] [Abstract][Full Text] [Related]
7. A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease.
Dahl IM; Solheim OP; Erikstein B; Müller E
Cancer; 1989 Jul; 64(1):68-73. PubMed ID: 2731122
[TBL] [Abstract][Full Text] [Related]
8. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
Erasmus JJ; Truong MT; Smythe WR; Munden RF; Marom EM; Rice DC; Vaporciyan AA; Walsh GL; Sabloff BS; Broemeling LD; Stevens CW; Pisters KM; Podoloff DA; Macapinlac HA
J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1364-70. PubMed ID: 15942579
[TBL] [Abstract][Full Text] [Related]
9. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
Grigoriu B; Chahine B; Zerimech F; Grégoire M; Balduyck M; Copin MC; Devos P; Lassalle P; Scherpereel A
Clin Biochem; 2009 Jul; 42(10-11):1046-50. PubMed ID: 19302997
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical differences between hyaluronan- and non-hyaluronan-producing malignant mesothelioma.
Thylén A; Levin-Jacobsen AM; Hjerpe A; Martensson G
Eur Respir J; 1997 Feb; 10(2):404-8. PubMed ID: 9042640
[TBL] [Abstract][Full Text] [Related]
11. Expression of hyaluronan synthases and hyaluronan in malignant mesothelioma cells.
Liu Z; Dobra K; Hauzenberger D; Klominek J
Anticancer Res; 2004; 24(2B):599-603. PubMed ID: 15161000
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
[TBL] [Abstract][Full Text] [Related]
13. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
[TBL] [Abstract][Full Text] [Related]
14. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
15. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
16. Serum hyaluronate in malignant pleural mesothelioma.
Frebourg T; Lerebours G; Delpech B; Benhamou D; Bertrand P; Maingonnat C; Boutin C; Nouvet G
Cancer; 1987 Jun; 59(12):2104-7. PubMed ID: 3567871
[TBL] [Abstract][Full Text] [Related]
17. Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results.
Plathow C; Staab A; Schmaehl A; Aschoff P; Zuna I; Pfannenberg C; Peter SH; Eschmann S; Klopp M
Invest Radiol; 2008 Oct; 43(10):737-44. PubMed ID: 18791416
[TBL] [Abstract][Full Text] [Related]
18. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F
Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622
[TBL] [Abstract][Full Text] [Related]
19. Serologic and histologic findings in patients with capsular contracture after breast augmentation with smooth silicone gel implants: is serum hyaluronan a potential predictor?
Prantl L; Pöppl N; Horvat N; Heine N; Eisenmann-Klein M
Aesthetic Plast Surg; 2005; 29(6):510-8. PubMed ID: 16328636
[TBL] [Abstract][Full Text] [Related]
20. Increased plasma concentrations of hyaluronan after major thermal injury in the rat.
Onarheim H; Reed RK; Laurent TC
Circ Shock; 1992 Jun; 37(2):159-63. PubMed ID: 1511507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
